Meeting
2022 ASCO Annual Meeting
Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.
Authors
Antoni Ribas
UCLA, Los Angeles, CA
Antoni Ribas , Pier Francesco Ferrucci , Victoria Atkinson , Rosalie Stephens , Georgina V. Long , Donald P. Lawrence , Michele Del Vecchio , Omid Hamid , Henrik Schmidt , Jacob Schachter , Paola Queirolo , Wilson H. Miller Jr., Matteo S. Carlino , Anna Maria Di Giacomo , Inge Marie Svane , Razi Ghori , Rohini Singh , Scott J. Diede , Paolo Antonio Ascierto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT02130466
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9516)
DOI
10.1200/JCO.2022.40.16_suppl.9516
Abstract #
9516
Poster Bd #
109
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase 3 trial of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus pembrolizumab in patients with previously untreated unresectable locally advanced or metastatic melanoma.
First Author: Ana Baramidze
Poster
2022 ASCO Annual Meeting
Pembrolizumab (pembro) plus mFOLFOX7 or FOLFIRI for metastatic colorectal cancer (CRC) in KEYNOTE-651: Long-term follow-up of cohorts B and D.
First Author: Richard D. Kim
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas
Poster
2022 ASCO Annual Meeting
KeyVibe-008: Randomized, phase 3 study of first-line vibostolimab plus pembrolizumab plus etoposide/platinum versus atezolizumab plus EP in extensive-stage small cell lung cancer.
First Author: Jacob Sands